Table 1 Patient Samples Analyzed in this Study

317

59

CEPI

serous adenocarcinoma

Ic

3

N/A

postmenopausal

336

63

CEPI

serous adenocarcinoma

Ic

3

N/A

postmenopausal

367

56

CEPI

serous adenocarcinoma

II

3

N/A

postmenopausal

242

63

CEPI

serous adenocarcinoma

IIb

3

N/A

postmenopausal

183

66

CEPI

serous adenocarcinoma

III

2

N/A

postmenopausal

413

49

CEPI

serous adenocarcinoma

III

3

N/A

postmenopausal

229

58

CEPI

serous adenocarcinoma

IIIc

3

N/A

postmenopausal

369

52

CEPI

serous adenocarcinoma

IIIc

2

N/A

postmenopausal

528

66

CEPI

serous adenocarcinoma

IIIc

3

N/A

postmenopausal

588

71

CEPI

serous adenocarcinoma

IIIc

2/3

N/A

postmenopausal

489

48

CEPI

serous adenocarcinoma

IIIc-IV

3

N/A

perimenopausal

542

61

CEPI

serous adenocarcinoma

IV

3

N/A

postmenopausal

434

41

OSE

WNL

N/A

N/A

atypical complex hyperplasia in polypoid endometrium

perimenopausal

437

54

OSE

WNL

N/A

N/A

cervical adenocarcinoma

postmenopausal

440

50

OSE

WNL

N/A

N/A

uterine myoma

perimenopausal

448

63

OSE

WNL

N/A

N/A

uterine myoma

postmenopausal

452

51

OSE

WNL

N/A

N/A

endometrial adenocarcinoma

perimenopausal

463

48

OSE

WNL

N/A

N/A

endometrial adenocarcinoma

perimenopausal

470

44

OSE

WNL

N/A

N/A

endometrial adenocarcinoma

premenopausal

475

63

OSE

WNL

N/A

N/A

benign simple cyst in right ovary; left ovary brushing used for microarray

postmenopausal

541

41

OSE

WNL

N/A

N/A

adenomyosis uteri and endometriosis

perimenopausal

552

41

OSE

WNL

N/A

N/A

prophylactic TAH-BSO, previous breast and vulval cancer and family history

premenopausal

563

66

OSE

WNL

N/A

N/A

endometrial adenocarcinoma

postmenopausal

567

77

OSE

WNL

N/A

N/A

endocervical adenocarcinoma

postmenopausal